

Supplemental Table S2: FDA Approval Summary: (Daunorubicin and Cytarabine) Liposome for Injection for the Treatment of Adults with High-Risk Acute Myeloid Leukemia

Supplemental Table S2: Prolonged Cytopenia on Study 301

	Induction 1		Consolidation 1^b	
	Vyxeos N=58	7+3 N=34	Vyxeos N=48	5+2 N=32
Prolonged thrombocytopenia ^a	16 (28)	4 (12)	12 (25)	5 (16)
Prolonged neutropenia ^a	10 (17)	1 (3)	5 (10)	1 (3)

^a Platelets < 50 Gi/L or neutrophils < 0.5 Gi/L lasting past cycle day 42 in the absence of active leukemia.

^b For patients receiving at least 1 consolidation.